Literature & market: what the evidence actually supports
Six independent research streams โ clinical evidence, competitor landscape, market size & willingness-to-pay, regulation, wearables/biofeedback, and user sentiment โ were pulled into one synthesis, then adversarially fact-checked claim by claim against primary sources. This page carries only what survived that check, in the form it was corrected to.
Source: research/SYNTHESIS.md, compiled from a 6-angle fact-checked research sweep ยท every numeric claim below was re-opened against its cited primary source and marked CONFIRMED, CORRECTED or UNSUPPORTED before being used here.
Music reliably reduces anxiety โ but the effect size depends on which study you read
Four independent meta-analyses converge on a genuine anti-anxiety effect of music listening, but the pooled effect size ranges from dโโ0.30 to dโโ0.97 depending on population, outcome type (self-report vs. physiological) and how strictly the review screens for trial quality.
STAI-S anxiety units [95% CI โ7.27, โ4.17] across 26 trials, N=2,051; one N=327 trial matched the sedative midazolam. GRADE: low quality (no blinding).
Bradt, Dileo & Shim (2013), Cochrane CD006908 โ source
Psychological vs. physiological stress reduction across 104 RCTs (N=9,617). Heart rate is the strongest physiological marker (d=.456); cortisol the weakest (d=.349).
de Witte et al. (2020), Health Psychology Review โ source
[95% CI โ1.26, โ0.28] across 21 controlled studies; rises to d=โ0.97 in a low-bias-only sensitivity subset (k=10).
Harney et al. (2023), Musicae Scientiae โ source
Music therapy, music medicine and receptive delivery achieve a similar SMD on anxiety (k=23, n=1,084) โ but GRADE "very low" and not maintained at follow-up.
Lassner et al. (2024/2025), BJPsych Open โ source
| Claim | Source | Evidence type |
|---|---|---|
| Perioperative music reduces state anxiety by โ5.72 STAI-S units; comparable to midazolam in one trial | Bradt, Dileo & Shim, 2013 (Cochrane CD006908) | Cochrane review ยท 26 RCTs, N=2,051 ยท GRADE low |
| Music reduces physiological stress (d=.380) and psychological stress (d=.545); cortisol weakest at d=.349 | de Witte et al., 2020, Health Psychology Review | Meta-analysis ยท 104 RCTs, N=9,617 |
| Music reduces anxiety with d=โ0.77, rising to โ0.97 in low-bias studies | Harney et al., 2023, Musicae Scientiae | Meta-analysis ยท 21 controlled studies |
| Therapist-led, passive-listening and receptive delivery modes achieve similar anxiety effects (SMD=0.47); not sustained at follow-up | Lassner et al., 2024/2025, BJPsych Open | Meta-review ยท GRADE very low |
| Slow-tempo (60โ80 BPM), relaxing music raises parasympathetic/vagal tone (HRVโ); fast tempo shifts toward sympathetic dominance (HRVโ) | Bernardi, Porta & Sleight, 2006, Circulation; Mitrovic & Paladin, 2026, Front. Cardiovasc. Med. | Controlled physiology study + 2026 review |
| Self-reported anxiety drops significantly (d=โ0.30); the psychophysiological effect is not statistically significant | Panteleeva et al., 2018, Psychology of Music | Meta-analysis ยท caution / counterweight |
Effect sizes span d=โ0.30 to d=โ0.97 โ and self-report doesn't always track physiology
Every review agrees music reduces anxiety; none agree by how much. The spread reflects differing inclusion criteria (clinical vs. non-clinical samples, control conditions, outcome type). Cortisol โ the marker closest to a "stress hormone" claim โ is consistently the weakest of the three physiological markers [de Witte et al., 2020], and self-report and physiological anxiety measures do not always move together [Panteleeva et al., 2018]. Any claim that leans on "music reduces anxiety" should name which review, which outcome, and which population it means.
A growing category, built on top of very different anxiety rates
Market-research firms diverge sharply by category definition; anxiety-prevalence estimates diverge even more sharply by country and diagnostic instrument.
2025 โ 2033, 14.7% CAGR; North America ~43% share.
Grand View Research, 2025 โ source
2025 โ 2034, 19.2% CAGR โ a broader category than meditation-only; not directly comparable.
Fortune Business Insights, 2025 โ source
2024, forecast >ยฅ4.5T by 2029 โ bundles blind-box toys, pets, escape rooms; not an app-specific figure.
iiMedia, 2025 โ source
People with an anxiety disorder, 2021 (~4.4% of world population); only 27.6% receive treatment.
WHO, 2023 โ source
| Region | 12-month prevalence | Lifetime prevalence | Source |
|---|---|---|---|
| China | 5.0% | 7.6% | Huang et al., 2019, The Lancet Psychiatry |
| United States | 19.1% | 31.1% | NIMH, NCS-R survey |
| Global | ~4.4% (359M people) | โ | WHO, 2023 |
The roughly 4ร gap between the China and US figures is best read as a measurement artifact โ underdiagnosis, stigma and differing diagnostic instruments โ rather than a true 4ร difference in psychological distress [Huang et al., 2019]; [NIMH].
Willingness to pay differs by market as much as prevalence estimates do: Calm prices its annual plan at $69.99 [Business of Apps, 2026]; China's leading meditation app, Tide (ๆฝฎๆฑ), prices its annual plan at roughly ยฅ218 (~$30) โ about 40% of Calm's price [SSPai, 2026].
Forecasts say growth; incumbents say maturity
Grand View Research and Fortune Business Insights both forecast double-digit CAGR through the early 2030s โ yet Calm's own 2025 numbers show revenue down 24% year-on-year to about $210M and subscribers down roughly 500,000 [Business of Apps, 2026]. Headspace shows a similar softening. Category-level growth forecasts and incumbent-level performance are telling two different stories, and both should be held at once, not resolved in favour of one.
Wellness, not medicine โ a line every regulator draws, but draws differently
US, EU/Germany and China all separate low-risk "wellness" claims from regulated "treatment" claims โ but where that line falls, and what it costs to cross it, differs by market.
| Market | Wellness-safe language | What triggers medical/regulatory status |
|---|---|---|
| US (FDA) | "Helps you relax," "supports stress management" โ general-wellness two-factor test (low risk + lifestyle-only intent) | "Treats anxiety disorder," diagnosing a named condition โ Software-as-a-Medical-Device (SaMD), requiring 510(k)/De Novo clearance |
| EU / Germany (DiGA) | Unlimited wellness/lifestyle claims outside the DiGA reimbursement system | Claiming a therapeutic benefit for a named ICD-10 condition + seeking reimbursement โ CE-marked medical device + BfArM DiGA Fast-Track clinical evidence |
| China | "ๆ ็ปช็ฎก็" (mood management), "ๅๅ" (stress relief), "ๅฅๅบท็ฎก็" (health management) โ no diagnostic or treatment claim | "ๆฒป็็ฆ่" (treat anxiety) โ barred by Advertising Law Art. 17 (fines of 1โ3ร ad spend or ยฅ100,000โ200,000); AI-driven diagnosis/treatment software risks NMPA Class III classification |
Sources: FDA General Wellness guidance ยท BfArM DiGA-Verzeichnis ยท Advertising Law of the PRC, via Zhonglun, 2026
Germany's DiGA registry lists roughly 60 apps, and mental health (anxiety, depression, sleep) is the single largest category (31 of 60) [BfArM DiGA-Verzeichnis, 2026] โ but clinician skepticism is real: in a 2022 survey of ~2,600 German physicians, 27.7% considered DiGAs prescribed for depression ineffective or contraindicated [Schmitz et al., 2025].
Maker of the first FDA-cleared prescription digital therapeutic filed for bankruptcy despite clinical and regulatory success.
Fierce Biotech, 2023 โ source
EndeavorRx's maker was delisted from Nasdaq and taken private after a failed prescription-to-OTC pivot.
Nasdaq/BusinessWire, 2024 โ source
Both major US digital-therapeutic precedents reached clearance and still failed commercially
Pear and Akili both achieved genuine FDA clearance โ and both still failed commercially. Reimbursement, not clinical efficacy, was the repeatedly cited constraint. Medicare only began reimbursing FDA-cleared digital mental-health devices from January 2025 (HCPCS G0552โG0554), and clinician cost-fronting has limited uptake so far [Healthcare Brew, 2025].
The "real-time biometric loop" is mostly heart rate, not HRV
A closed-loop product concept rests on one assumption: that a wearable can feed live physiological state back into the audio. The data says that's true for heart rate โ and not yet true for HRV.
Real-time HRV is not continuously available on today's consumer platforms
Apple HealthKit exposes HRV (SDNN) to third-party apps only with explicit permission, and only as opportunistically-sampled values around Mindfulness/Breathe sessions and background rest โ not a continuous stream. Only plain heart rate can update every few seconds; HRV itself can lag up to ~30 minutes [Apple Developer Forums, cited in Wearables-verified, 2026]. Oura's API returns HRV/heart-rate at 5-minute granularity, but only captured during sleep and released the following morning โ there is no live endpoint, and since 2024 Oura has paywalled this data behind an active Membership subscription for newer rings [Oura developer documentation, 2024]. Any "real-time HRV-adaptive" product claim needs to be scoped to what's actually available โ live heart rate, next-morning HRV โ not live HRV.
| Data source | What's actually available | Real-time? |
|---|---|---|
| Apple HealthKit โ heart rate | Updates every few seconds during an active session | Yes |
| Apple HealthKit โ HRV (SDNN) | Opportunistic samples around Mindfulness/rest; can lag up to ~30 minutes | No |
| Oura Ring API | 5-minute HRV/HR granularity, sleep-only, released the next morning; paywalled behind Membership for Gen3+/Ring 4 (2024) | Next-day only |
| Endel's closed loop (current market precedent) | Real-time Apple Watch heart rate (not HRV) + motion, time of day, light | HR only |
Series 9/Ultra 2 underestimated HRV against a Polar H10 chest-strap reference (MAPE 28.9%), failing pre-set equivalence bounds โ though resting heart rate was accurate (5.9% error).
Sensors, 2024 โ source
Pre-post and vs.-control effect of HRV-biofeedback training on stress/anxiety, across 24 studies (n=484) โ the strongest indirect evidence for a closed loop, but for breathing-paced biofeedback, not music-driven adaptive audio.
Goessl, Curtiss & Hofmann, 2017 โ source
Endel remains the clearest commercial precedent for closed-loop biometric-adaptive audio โ using real-time Apple Watch heart rate (not HRV) plus motion, time of day and light, and winning Apple's "Watch App of the Year" in 2020 โ but no independent, peer-reviewed outcome study of Endel or any comparable commercial biometric-adaptive audio app was found [Wearables-verified, 2026]. This is a genuine generalization gap worth naming explicitly: Goessl et al. (2017) validates HRV-biofeedback protocols generally โ it is not direct evidence that music-driven adaptive audio produces the same effect [Goessl, Curtiss & Hofmann, 2017].